Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-Current Debt: 2020-2022

  • SAB Biotherapeutics' Non-Current Debt was N/A to $541,644 in Q4 2022 from the same period last year, while for Dec 2022 it was $541,644, marking a year-over-year change of. This contributed to the annual value of $541,644 for FY2022, which is N/A change from last year.
  • Per SAB Biotherapeutics' latest filing, its Non-Current Debt stood at $541,644 for Q4 2022, which was up 214.84% from $172,037 recorded in Q4 2020.
  • SAB Biotherapeutics' 5-year Non-Current Debt high stood at $541,644 for Q4 2022, and its period low was $172,037 during Q4 2020.
  • In the last 2 years, SAB Biotherapeutics' Non-Current Debt had a median value of $356,840 in 2020 and averaged $356,840.